Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) – Pipeline Review, H1 2018’, provides in depth analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Hematological Disorders, Ophtthalmology and Respiratory under development targeting Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

– The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

CJ HealthCare Corp

Concert Pharmaceuticals Inc

Eli Lilly and Co

Galapagos NV

Han Wha Pharma Co Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

LEO Pharma A/S

Nissan Chemical Industries Ltd

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Drug Profiles

ABBV-599 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-52793 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-0184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIP-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04965842 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06700841 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-20347 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SART-29 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-0302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Jak1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upadacitinib tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata

Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

Apr 23, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia

Apr 09, 2018: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis

Feb 17, 2018: AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

Feb 16, 2018: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn’s Disease at 52 Weeks

Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting

Feb 14, 2018: Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

Feb 12, 2018: AbbVie to Present Data on Upadacitinib at 2018 American Academy of Dermatology Annual Meeting

Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata

Feb 08, 2018: Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy

Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by Aclaris Therapeutics Inc, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by CJ HealthCare Corp, H1 2018

Pipeline by Concert Pharmaceuticals Inc, H1 2018

Pipeline by Eli Lilly and Co, H1 2018

Pipeline by Galapagos NV, H1 2018

Pipeline by Han Wha Pharma Co Ltd, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Japan Tobacco Inc, H1 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Pipeline by LEO Pharma A/S, H1 2018

Pipeline by Nissan Chemical Industries Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Portola Pharmaceuticals Inc, H1 2018

Pipeline by Sareum Holdings Plc, H1 2018

Pipeline by Theravance Biopharma Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports